Development of oral combination biologic agents against shrimp multiple pathogens

View Statistics Email Alert RSS Feed

Information

Details

Project title

Code/計畫編號

MOST109-2622-B019-008

Translated Name/計畫中文名

開發抗蝦類多重病原體之口服複合式生物製劑

Project Coordinator/計畫主持人

Li-Li Chen

Funding Organization/主管機關

National Science and Technology Council

Department/Unit

Institute of Marine Biology

Website

https://www.grb.gov.tw/search/planDetail?id=13609562

Year

2020

Start date/計畫起

01-11-2020

Expected Completion/計畫迄

31-10-2021

Bugetid/研究經費

1000千元

ResearchField/研究領域

漁業

聯合國估計，世界人口在2100年將進一步增加到112億。人口不斷增加，我們必須在有限的資源下創造足夠的糧食，水產品成為提供優良的營養與廉價的食物來源之一。然而在高密度集約養殖之下，加上水質管理不當與氣候急遽變化，許多疾病因此爆發。根據全球水產養殖聯盟統計，亞洲地區在1991~2005年15年間養蝦產業因疾病爆發所造成的損失達120億美元，其中因病毒性疾病所造成的損失約佔60%、細菌性疾病約佔20%，剩餘約20%為其他病原體 (如：寄生蟲和真菌)、非生物因子或不明原因。白點症與急性肝胰臟壞死綜合症是當前威脅蝦類養殖最主要的疾病，白點症的病原體是白點症病毒，急性肝胰臟壞死綜合症的病原體為副溶血弧菌變異株。在白點症的防治方面我們已成功開發出白點症病毒入侵抑制物並達商品化階段，但對於急性肝胰臟壞死綜合症則尚無解決方法。在我們過去的相關研究中發現白蝦腸道天然存在數種細菌，在蝦感染急性肝胰臟壞死綜合症之後數量有急遽變動的現象，已分離出一種菌代號為CS60，此菌具有抑制急性肝胰臟壞死綜合症病原體弧菌的能力，也證實可引起藍蝦的數種免疫能力。因此本研究分兩年進行，第一年將利用這些天然的、已存在的腸道菌CS60搭配GRAS (Generally Recognized as Safe) 枯草桿菌，先發展出可對抗急性肝胰臟壞死綜合症之複合式腸道益生菌產品原型；第二年以第一年成果再搭配已發展出的抗蝦白點症病毒入侵抑制物Inno A1，製作出能同時防治白點症與急性肝胰臟壞死綜合症的口服抗蝦類多重病原複合式生物製劑，達到不使用藥物亦可讓蝦類自然成長、減少死亡，塑造無毒養殖環境。此複合式生物製劑將具備複合腸道益生菌產品的優點及對抗蝦類白點症與急性肝胰臟壞死綜合症的精準醫療概念，可以更全面防治蝦類疾病。The United Nations estimates that the world population will further increase to 11.2 billion by the year of 2100. With a growing population, we must create enough food with limited resources. Aquatic products have become one of the sources of good nutrition and cheap food. However, with high-density intensive farming, coupled with improper water quality management and rapid climate change, many diseases have occurred. Reviewing in some publications about shrimp aquaculture industry in Asia, the production losses due to disease over the preceding 15 years (from 1991 to 2005) had amounted to approximately 12 billion USD. According to a survey in shrimp aquaculture conducted by the Global Aquaculture Alliance (GAA), approximately 60% of disease losses could be attributed to viral diseases, 20% to bacterial diseases and the remaining 20% to a variety of other pathogens (for example, parasites and fungi) and to abiotic or unknown causes. White spot syndrome (WSS) and acute hepatopancreatic necrosis disease (AHPND) are currently the most important diseases that threaten shrimp aquaculture. The pathogen of WSS is white spot syndrome virus (WSSV), and the pathogen of AHPND is a mutant strain of Vibrio parahaemolyticus, called VPAHPND. In the prevention and treatment of WSS, we have successfully developed the inhibitor for WSSV infection and reached the commercial stage, but there is still no solution for acute AHPND. In our previous studying, several kinds of bacteria were found in the intestines of white shrimps (Litopenaeus vannamei) naturally. The population numbers are rapidly changed after the shrimps infected with VPAHPND. A strain with the code name CS60 has been isolated. This strain shows the ability to inhibit VPAHPND. It has also been shown to induce several immune genes in blue shrimp (L. stylirostris). Therefore, this proposal was conducted in two years. In the first year, we will use the natural and existing intestinal bacterium CS60 together with generally recognized as safe (GRAS) Bacillus subtilis to develop an intestinal probiotic product prototype that can combat AHPND. In the second year, combined the prototype with the developed WSSV inhibitor Inno A1, an oral combination biologic agents capable of preventing WSS and AHPND has been developed. This combination biologic agent can also allow shrimp to grow naturally, reduce mortality and create a non-toxic aquaculture environment. This combination biologic agent will have the advantages of the intestinal probiotic product and the precision medicine concept of Inno A1, which can more comprehensively prevent shrimp diseases.

Keyword(s)

白蝦
病原體
白點症
急性肝胰臟壞死綜合症
益生菌
白點症病毒入侵抑制物
複合式生物製劑
White shrimps (Litopenaeus vannamei)
pathogens
white spot syndrome (WSS)
acute hepatopancreatic necrosis disease (AHPND)
probiotic
Inno A1
combination biologic agents

DSpace CRIS

Development of oral combination biologic agents against shrimp multiple pathogens

Details

Description